Evidence map›Paper›PMID 35655319›Full record

SynthesisJournal of experimental & clinical cancer research : CR2022

Focal Adhesion Kinase (FAK)-Hippo/YAP transduction signaling mediates the stimulatory effects exerted by S100A8/A9-RAGE system in triple-negative breast cancer (TNBC).

Damiano Cosimo Rigiracciolo, Nijiro Nohata, Rosamaria Lappano, Francesca Cirillo, Marianna Talia, Sendi Rafael Adame-Garcia, Nadia Arang, Simone Lubrano, Ernestina Marianna De Francesco, Antonino Belfiore and 2 more

Abstract readMeta-Analysis
In one paragraph

Synthesis in Journal of experimental & clinical cancer research : CR, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.

0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

38 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Asparagine endopeptidase prompts breast cancer-related pericardial calcification by regulating IGF2 and integrin αvβ5.Proceedings of the National Academy of Sciences of the United States of America · 2025
    Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Damiano Cosimo RigiraccioloDepartment of Pharmacy, Health and Nutritional Sciences, University of Calabria, 87036, Rende, Italy.
Nijiro NohataMSD K.K., Tokyo, 102-8667, Japan.
Rosamaria LappanoDepartment of Pharmacy, Health and Nutritional Sciences, University of Calabria, 87036, Rende, Italy.
Francesca CirilloDepartment of Pharmacy, Health and Nutritional Sciences, University of Calabria, 87036, Rende, Italy.
Marianna TaliaDepartment of Pharmacy, Health and Nutritional Sciences, University of Calabria, 87036, Rende, Italy.
Sendi Rafael Adame-GarciaMoores Cancer Center, University of California, San Diego, La Jolla, CA, USA.
Nadia ArangMoores Cancer Center, University of California, San Diego, La Jolla, CA, USA.
Simone LubranoMoores Cancer Center, University of California, San Diego, La Jolla, CA, USA.
Ernestina Marianna De FrancescoDepartment of Clinical and Experimental Medicine, University of Catania, Garibaldi-Nesima Hospital, Catania, Italy.
Antonino BelfioreDepartment of Clinical and Experimental Medicine, University of Catania, Garibaldi-Nesima Hospital, Catania, Italy.
J Silvio GutkindMoores Cancer Center, University of California, San Diego, La Jolla, CA, USA. sgutkind@ucsd.edu.
Marcello MaggioliniDepartment of Pharmacy, Health and Nutritional Sciences, University of Calabria, 87036, Rende, Italy. marcello.maggiolini@unical.it.

Funding

Associazione Italiana per la Ricerca sul Cancro 21322Associazione Italiana per la Ricerca sul Cancro 21651Associazione Italiana per la Ricerca sul Cancro 23369
6 · The paper itself

Abstract

backgroundUnderstanding the intricate signaling network involved in triple-negative breast cancer (TNBC) represents a challenge for developing novel therapeutic approaches. Here, we aim to provide novel mechanistic insights on the function of the S100A8/A9-RAGE system in TNBC.

methodsTNM plot analyzer, Kaplan-Meier plotter, Meta-analysis, GEPIA2 and GOBO publicly available datasets were used to evaluate the clinical significance of S100A8/A9 and expression levels of S100A8/A9, RAGE and Filamin family members in breast cancer (BC) subtypes. METABRIC database and Cox proportional hazard model defined the clinical impact of high RAGE expression in BC patients. Multiple bioinformatics programs identified the main enriched pathways within high RAGE expression BC cohorts. By lentiviral system, TNBC cells were engineered to overexpress RAGE. Western blotting, immunofluorescence, nucleus/cytoplasm fractionation, qRT-PCR, gene silencing and luciferase experiments were performed to identify signal transduction mediators engaged by RAGE upon stimulation with S100A8/A9 in TNBC cells. Proliferation, colony formation and transwell migration assays were carried out to evaluate the growth and migratory capacity of TNBC cells. Statistical analysis was performed by ANOVA and independent t-tests.

resultsWe found a remarkable high expression of S100A8 and S100A9 in BC, particularly in HER2-positive and TNBC, with the latter associated to worst clinical outcomes. In addition, high RAGE expression correlated with a poor overall survival in BC. Next, we determined that the S100A8/A9-RAGE system triggers FAK activation by engaging a cytoskeleton mechanosensing complex in TNBC cells. Through bioinformatics analysis, we identified the Hippo pathway as the most enriched in BC patients expressing high RAGE levels. In accordance with these data, we demonstrated the involvement of S100A8/A9-RAGE-FAK signaling in the control of Hippo/YAP activities, and we established the crucial contribution of RAGE-FAK-YAP circuitry in the growth and migratory effects initiated by S100A8/A9 in TNBC cells.

conclusionsThe present study provides novel mechanistic insights on RAGE actions in TNBC. Moreover, our findings suggest that RAGE-FAK-YAP transduction pathway could be exploited as a druggable system halting the aggressive TNBC subtype.

Indexed as

Triple Negative Breast NeoplasmsCell AdhesionFocal Adhesion Protein-Tyrosine KinasesHippo Signaling PathwayHumansSignal TransductionFocal Adhesion Protein-Tyrosine KinasesBT-549FAKHippo/YAPMDA-MB-231RAGES100A8/A9TNBC

Identifiers

PMID35655319
PMCPMC9164429

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.